Consistent with our results, previous landmark trials such as EMPA-REG OUTCOME and DAPA-HF have demonstrated thecardioprotective effects of SGLT2 inhibitors in reducing hospitalization for heart failure and cardiovascular mortality, even innon-diabetic populations [1, 2]. Here, SLC5A2 is linked to heart failure.